detalle del documento
IDENTIFICACIÓN

doi:10.1038/s42003-023-04793-3...

Autor
Dzimianski, John V. Han, Julianna Sautto, Giuseppe A. O’Rourke, Sara M. Cruz, Joseph M. Pierce, Spencer R. Ecker, Jeffrey W. Carlock, Michael A. Nagashima, Kaito A. Mousa, Jarrod J. Ross, Ted M. Ward, Andrew B. DuBois, Rebecca M.
Langue
en
Editor

Nature

Categoría

Life Sciences

Año

2023

fecha de cotización

26/4/2023

Palabras clave
computationally influenza vaccine hemagglutinin optimized cobra
Métrico

Resumen

Structural studies of a computationally optimized broadly reactive antigen hemagglutinin in complex with a broadly neutralizing antibody reveal its immunogenic properties and provide insights into flu vaccine design.

Influenza virus poses an ongoing human health threat with pandemic potential.

Due to mutations in circulating strains, formulating effective vaccines remains a challenge.

The use of computationally optimized broadly reactive antigen (COBRA) hemagglutinin (HA) proteins is a promising vaccine strategy to protect against a wide range of current and future influenza viruses.

Though effective in preclinical studies, the mechanistic basis driving the broad reactivity of COBRA proteins remains to be elucidated.

Here, we report the crystal structure of the COBRA HA termed P1 and identify antigenic and glycosylation properties that contribute to its immunogenicity.

We further report the cryo-EM structure of the P1-elicited broadly neutralizing antibody 1F8 bound to COBRA P1, revealing 1F8 to recognize an atypical receptor binding site epitope via an unexpected mode of binding.

Dzimianski, John V.,Han, Julianna,Sautto, Giuseppe A.,O’Rourke, Sara M.,Cruz, Joseph M.,Pierce, Spencer R.,Ecker, Jeffrey W.,Carlock, Michael A.,Nagashima, Kaito A.,Mousa, Jarrod J.,Ross, Ted M.,Ward, Andrew B.,DuBois, Rebecca M., 2023, Structural insights into the broad protection against H1 influenza viruses by a computationally optimized hemagglutinin vaccine, Nature

Documento

Abrir

Compartir

Fuente

Artículos recomendados por ES/IODE IA

Systematic druggable genome-wide Mendelian randomization identifies therapeutic targets for lung cancer
agphd1 subtypes replication hykk squamous cell gene carcinoma causal targets mendelian randomization cancer analysis